The drug company Corbus Pharmaceuticals will start its next Phase 2 clinical trial to test a potential inflammation-targeting drug in people with cystic fibrosis in the first quarter of 2018.
Site Search
Showing 51 - 60 of 745 results
News
|
Jan. 30, 2018
|
3 min read
Icagen Inc. will focus on drug discovery, screening for compounds that could suppress nonsense mutations, and using computer modeling to identify molecules that are suitable to be developed into drugs.
News
|
May 1, 2018
|
2 min read
The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.
News
|
Nov. 17, 2010
|
3 min read
This year, Cystic Fibrosis Advocates inspired new champions in Washington, D.C. and in state capitols across the country to take action on critical CF-related issues.
News
|
Dec. 10, 2010
|
2 min read
News
|
Oct. 11, 2011
|
1 min read
News
|
Nov. 20, 2008
|
1 min read
Press Release
|
Jan. 23, 2008
|
6 min read
Press Release
|
March 26, 2008
|
4 min read
Press Release
|
March 20, 2008
|
3 min read
Nationwide Effort to Instill Best Practices for Cystic Fibrosis Care is Honored for Excellence
Press Release
|
Oct. 21, 2008
|
3 min read